Form 4: Whitehawk Therapeutics CEO Trades Shares

Whitehawk Therapeutics CEO David James Lennon reported transactions involving company stock, including the acquisition of restricted stock units and stock options, and the sale of shares to cover tax obligations.

Summary

• David James Lennon, CEO of Whitehawk Therapeutics, Inc., reported several transactions on April 1st and 2nd, 2026.
• He acquired 775,828 restricted stock units (RSUs).
• These RSUs are set to vest over one year, starting from April 1, 2025, contingent on continued service.
• Lennon also acquired stock options to purchase 831,148 shares of common stock at an exercise price of $3.54.
• These options have a vesting schedule of 25% on the first anniversary of April 1, 2026, with the remainder vesting monthly over the subsequent three years.
• Additionally, 26,858 shares were sold at $3.48 per share to cover tax withholding obligations related to the vesting of RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting standard executive compensation and tax-related share sales rather than significant new strategic information or performance indicators.

Positives

• Acquisition of a significant number of restricted stock units (775,828) by the CEO, indicating continued commitment and potential future value.
• Granting of stock options (831,148) to the CEO with a clear vesting schedule, aligning executive incentives with long-term company performance.
• The CEO's continued role as Director and Chief Executive Officer suggests stability in leadership.

Negatives

• Sale of 26,858 shares by the CEO to cover tax withholding obligations, which, while standard, represents a reduction in direct share ownership.

Risks

• The vesting of RSUs and stock options is contingent on the reporting person continuing to be a Service Provider, implying a risk of forfeiture if employment or service is terminated.
• The stock option exercise price of $3.54 suggests that the company's stock price needs to exceed this level for the options to be profitable.

Future Outlook

The vesting schedules for RSUs and stock options indicate a long-term incentive structure for the CEO, tied to continued service and the company's future performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of RSUs and stock options by a CEO is typical for aligning executive interests with shareholder value, especially in growth-oriented biotechnology companies like Whitehawk Therapeutics.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation and do not immediately indicate a change in company strategy or performance. The vesting of equity awards may dilute ownership slightly over time but also aligns executive incentives.
• Employees: The CEO's compensation structure, including equity awards, is part of the company's overall compensation strategy.
• Management: The CEO's continued role and equity holdings reinforce their commitment to the company.

Next Steps

• Continued vesting of RSUs and stock options for the CEO, contingent on continued service.
• Potential exercise of stock options by the CEO if the stock price exceeds the exercise price of $3.54.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Whitehawk Therapeutics, David James Lennon, Beneficial Ownership, Vesting Schedule